Published in Neuro Oncol on December 01, 2010
Bufalin induces the interplay between apoptosis and autophagy in glioma cells through endoplasmic reticulum stress. Int J Biol Sci (2014) 0.95
Nongenomic Mechanisms of PTEN Regulation. Int J Cell Biol (2012) 0.86
Novel functional roles of caspase-related genes in the regulation of apoptosis and autophagy. Korean J Physiol Pharmacol (2016) 0.75
In silico resurrection of the major vault protein suggests it is ancestral in modern eukaryotes. Genome Biol Evol (2013) 0.75
TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21
AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 16.72
Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol Cell (2007) 7.09
The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem (2005) 6.27
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol (2000) 5.22
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem (2001) 4.00
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature (2008) 3.53
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A (2009) 2.55
Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 2.27
PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol (2002) 2.16
Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol (2000) 2.05
A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A (2006) 2.03
Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer (2002) 2.02
Direct identification of PTEN phosphorylation sites. FEBS Lett (2002) 1.80
The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci U S A (2008) 1.78
Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol (2005) 1.55
A role for nuclear PTEN in neuronal differentiation. J Neurosci (2000) 1.50
Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer (2002) 1.49
A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. Oncogene (2007) 1.44
Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell (2006) 1.38
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res (2005) 1.33
Class reunion: PTEN joins the nuclear crew. Oncogene (2005) 1.31
PTEN enters the nucleus by diffusion. J Cell Biochem (2005) 1.28
LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes. Hum Mol Genet (2005) 1.18
Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res (2007) 1.14
ATP modulates PTEN subcellular localization in multiple cancer cell lines. Hum Mol Genet (2008) 1.03
Nuclear localization of PTEN is regulated by Ca(2+) through a tyrosil phosphorylation-independent conformational modification in major vault protein. Cancer Res (2006) 1.03
Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose. Mol Carcinog (2008) 1.01
Homeoprotein Cdx2 and nuclear PTEN expression profiles are related to gastric cancer prognosis. APMIS (2007) 0.84
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev (2003) 4.62
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 4.12
FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell (2011) 3.58
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res (2005) 3.10
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Retracted Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. Cancer Res (2013) 2.75
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther (2009) 2.31
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer (2002) 2.03
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther (2007) 1.97
Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem (2003) 1.97
Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell (2007) 1.97
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol (2011) 1.92
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res (2006) 1.91
Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res (2002) 1.88
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res (2005) 1.83
Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res (2003) 1.80
The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res (2003) 1.80
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell (2011) 1.78
VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol (2008) 1.77
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol (2003) 1.75
Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res (2006) 1.74
Src activation regulates anoikis in human colon tumor cell lines. Oncogene (2002) 1.70
The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat (2004) 1.69
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest (2002) 1.57
Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol (2005) 1.55
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev (2013) 1.55
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res (2005) 1.54
Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem (2007) 1.54
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res (2009) 1.54
Src continues aging: current and future clinical directions. Clin Cancer Res (2007) 1.50
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol (2011) 1.50
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res (2011) 1.48
The value of cell line validation. Neuro Oncol (2012) 1.41
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res (2003) 1.41
c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis. Mol Cell (2007) 1.40
Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther (2006) 1.39
Polymorphisms of DNA repair genes and risk of glioma. Cancer Res (2004) 1.39
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res (2006) 1.38
Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res (2005) 1.34
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol (2002) 1.33
Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro Oncol (2013) 1.32
SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem (2007) 1.32
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol (2009) 1.30
Involvement of the conserved adaptor protein Alix in actin cytoskeleton assembly. J Biol Chem (2006) 1.30
AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest (2007) 1.30
Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway. J Biol Chem (2006) 1.29
PAX6 suppresses growth of human glioblastoma cells. J Neurooncol (2005) 1.27
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol (2010) 1.27
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol (2012) 1.27
Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis (2006) 1.26
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol (2006) 1.25
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs (2011) 1.24
Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res (2003) 1.23
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol (2008) 1.23
BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res (2011) 1.23
Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol (2011) 1.23
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol (2009) 1.21
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One (2009) 1.20
PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene. Cancer Res (2006) 1.20
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Aggregation of cancer in first-degree relatives of patients with glioma. Cancer Epidemiol Biomarkers Prev (2007) 1.17
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res (2003) 1.17
Exploratory analysis of the copy number alterations in glioblastoma multiforme. PLoS One (2008) 1.17
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol (2014) 1.17
AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells. J Cell Physiol (2007) 1.17
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol (2013) 1.15
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res (2006) 1.15
The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res (2005) 1.15
Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res (2007) 1.14
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene (2002) 1.14
c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas (2005) 1.14
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther (2005) 1.13
Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res (2007) 1.12